Join to View Full Profile
149 Sidney StreetAcceleron PharmaCambridge, MA 02139
Phone+1 617-576-2220
Dr. Sherman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1983 - 1987- MedStar Health Georgetown University/Georgetown HospitalResidency, Internal Medicine, 1980 - 1983
- Geisel School of Medicine at DartmouthClass of 1980
Certifications & Licensure
- MA State Medical License 1983 - 2026
- ME State Medical License Active through 2006
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 2 citationsCSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib.Hans Gelderblom, Albiruni A Razak, Matthew H Taylor, Todd M Bauer, Breelyn Wilky
Clinical Cancer Research. 2024-09-13 - 3 citationsThe INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor withexon 11 + 17/18 mutations.Suzanne George, Jean-Yves Blay, Ping Chi, Robin L Jones, César Serrano
Future Oncology. 2024-01-01 - 3 citationsPatient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study.Hans Gelderblom, Robin L Jones, Jean-Yves Blay, Suzanne George, Margaret von Mehren
European Journal of Cancer. 2023-10-01
Press Mentions
- Deciphera Announces First Patient Treated in Phase 1 Study of DCC-3116 in Patients with Advanced or Metastatic Tumors with a Mutant RAS or RAF GeneJune 30th, 2021
- Deciphera Pharmaceuticals, Inc. To Present Data from DCC-3014 and Ripretinib Programs at the Connective Tissue Oncology Society (CTOS) 2019 Annual MeetingNovember 13th, 2019
- Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2019 Financial ResultsNovember 4th, 2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: